×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
QNTM – quantum biopharma ltd. - class b subordinate voting shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
QNTM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/2
08:30 am
qntm
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
High
Report
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
4/1
08:16 am
qntm
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis [TheStreet.com]
High
Report
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis [TheStreet.com]
4/1
08:02 am
qntm
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
High
Report
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
3/30
09:55 am
qntm
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis [Yahoo! Finance]
High
Report
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis [Yahoo! Finance]
3/30
07:50 am
qntm
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
High
Report
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
3/27
07:58 pm
qntm
Quantum Biopharma Provides Corporate Update [Yahoo! Finance]
High
Report
Quantum Biopharma Provides Corporate Update [Yahoo! Finance]
3/27
08:59 am
qntm
Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status [Yahoo! Finance]
Medium
Report
Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status [Yahoo! Finance]
3/27
08:10 am
qntm
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
High
Report
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
08:30 am
qntm
Form 6-K Quantum Biopharma Ltd. For: Apr 02
High
Report
Form 6-K Quantum Biopharma Ltd. For: Apr 02
4/1
08:02 am
qntm
Form 6-K Quantum Biopharma Ltd. For: Apr 01
High
Report
Form 6-K Quantum Biopharma Ltd. For: Apr 01
3/30
07:50 am
qntm
Form 6-K Quantum Biopharma Ltd. For: Mar 30
High
Report
Form 6-K Quantum Biopharma Ltd. For: Mar 30
3/27
08:10 am
qntm
Form 6-K Quantum Biopharma Ltd. For: Mar 27
High
Report
Form 6-K Quantum Biopharma Ltd. For: Mar 27
3/26
04:03 pm
qntm
Form 20-F Quantum Biopharma Ltd. For: Dec 31
High
Report
Form 20-F Quantum Biopharma Ltd. For: Dec 31
3/26
08:00 am
qntm
Form 6-K Quantum Biopharma Ltd. For: Mar 26
Medium
Report
Form 6-K Quantum Biopharma Ltd. For: Mar 26
3/23
08:24 am
qntm
Form 6-K Quantum Biopharma Ltd. For: Mar 23
High
Report
Form 6-K Quantum Biopharma Ltd. For: Mar 23
2/3
09:20 am
qntm
Form SCHEDULE 13G/A Quantum Biopharma Ltd. Filed by: Malone Wealth Ventures LLC
Medium
Report
Form SCHEDULE 13G/A Quantum Biopharma Ltd. Filed by: Malone Wealth Ventures LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: